5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Selective Vulnerability of the Nucleus Basalis of Meynert Among Neuropathologic Subtypes of Alzheimer Disease

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Key Points

          Question

          Does the objective classification of neuropathologic subtypes of Alzheimer disease underlie variability in the accumulation of neurofibrillary tangles and loss of neurons in the nucleus basalis of Meynert?

          Findings

          This cross-sectional study of 1464 human brains found the fewest neurons in the nucleus basalis of Meynert in hippocampal sparing Alzheimer disease and greater accumulation of neurofibrillary tangle pathology, twice that observed in limbic predominant Alzheimer disease. Younger age at onset of cognitive symptoms was associated with greater accumulation of neurofibrillary tangles in hippocampal sparing and typical but not limbic predominant Alzheimer disease.

          Meaning

          These results help to characterize differential involvement of the nucleus basalis of Meynert among neuropathologic Alzheimer disease subtypes, which may contribute to the differential benefit of acetylcholinesterase inhibitor treatment, especially in patients with young-onset Alzheimer disease.

          Abstract

          Importance

          Corticolimbic patterns of neurofibrillary tangle (NFT) accumulation define neuropathologic subtypes of Alzheimer disease (AD), which underlie the clinical heterogeneity observed antemortem. The cholinergic system, which is the target of acetylcholinesterase inhibitor therapy, is selectively vulnerable in AD.

          Objective

          To investigate the major source of cholinergic innervation, the nucleus basalis of Meynert (nbM), in order to determine whether there is differential involvement of NFT accumulation or neuronal loss among AD subtypes.

          Design, Setting, and Participants

          In this cross-sectional study, retrospective abstraction of clinical records and quantitative assessment of NFTs and neuron counts in the nbM was completed in January 2019 at the Mayo Clinic using the Florida Autopsied Multi-Ethnic (FLAME) cohort, which had been accessioned from 1991 until 2015. The FLAME cohort is derived from the deeded autopsy program funded throughout the State of Florida’s memory disorder clinic referral services. Of the 2809 consecutively accessioned FLAME cohort, 1464 were identified as neuropathologically diagnosed AD cases and nondemented normal controls available for clinicopathologic assessment. Quantification of NFTs and neuronal density in the anterior nbM was performed blinded to neuropathologic groupings.

          Main Outcomes and Measures

          Demographic and clinical characteristics, including cognitive decline measured using the Mini-Mental State Examination score (range, 0-30), were evaluated. The anterior nbM was investigated quantitatively for neuronal loss and NFT accumulation.

          Results

          In total, 1361 AD subtypes and 103 nondemented controls were assessed. The median (interquartile range) age at death was 72 (66-80) years in hippocampal sparing (HpSp) AD, 81 (76-86) years in typical AD, and 86 (82-90) years in limbic predominant AD. The median (interquartile range) count per 0.125 mm 2 of thioflavin S–positive NFTs was highest in the nbM of HpSp AD (14 [9-20]; n = 163), lower in typical AD (10 [5-16]; n = 937), and lowest in limbic predominant AD (8 [5-11], n = 163) ( P < .001). The median (interquartile range) neuronal density per millimeters squared was lowest in HpSp AD cases (22 [17-28]; n = 148), higher in typical AD (25 [19-30]; n = 727), and highest in limbic predominant AD (26 [19-32]; n = 127) ( P = .002). Multivariable regression modeling of clinical and demographic variables was performed to assess overlap in NFT accumulation and neuronal density differences among AD subtypes. Higher NFT accumulation in the nbM was associated with younger age at onset for HpSp AD (β, −1.5; 95% CI, −2.9 to −0.15; P = .03) and typical AD (β, −3.2; 95% CI, −3.9 to −2.4; P < .001). In addition, higher NFT accumulation in the nbM of typical AD cases was associated with female sex (β, 2.5; 95% CI, 1.4-3.5; P < .001), apolipoprotein E ε4 allele (β, 1.3; 95% CI, 0.15-2.5; P = .03), and lower Mini-Mental State Examination scores (β, −1.8; 95% CI, −3.2 to −0.31; P = .02). Demographic and clinical progression variables were not associated with NFT accumulation in the nbM of limbic predominant AD cases.

          Conclusions and Relevance

          These data provide supportive evidence that NFT accumulation in the nbM may underlie more widespread and severe cholinergic deficits in young-onset AD, in particular in patients with HpSp AD. Moreover, these findings underscore the importance of considering age at onset, sex, and apolipoprotein E genotype when assessing outcomes in AD.

          Abstract

          This cross-sectional study using tissue from the Florida Autopsied Multi-Ethnic cohort assesses whether an association exists between neuropathologic subtypes of Alzheimer disease and neurofibrillary tangle accumulation or neuron loss in the nucleus basalis of Meynert, a major source of brain cholinergic innervation.

          Related collections

          Most cited references29

          • Record: found
          • Abstract: found
          • Article: not found

          National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach.

          We present a practical guide for the implementation of recently revised National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease (AD). Major revisions from previous consensus criteria are: (1) recognition that AD neuropathologic changes may occur in the apparent absence of cognitive impairment, (2) an "ABC" score for AD neuropathologic change that incorporates histopathologic assessments of amyloid β deposits (A), staging of neurofibrillary tangles (B), and scoring of neuritic plaques (C), and (3) more detailed approaches for assessing commonly co-morbid conditions such as Lewy body disease, vascular brain injury, hippocampal sclerosis, and TAR DNA binding protein (TDP)-43 immunoreactive inclusions. Recommendations also are made for the minimum sampling of brain, preferred staining methods with acceptable alternatives, reporting of results, and clinico-pathologic correlations.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE

            P DAVIES (1976)
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey.

                Bookmark

                Author and article information

                Journal
                JAMA Neurol
                JAMA Neurol
                JAMA Neurol
                JAMA Neurology
                American Medical Association
                2168-6149
                2168-6157
                28 October 2019
                February 2020
                6 January 2020
                28 October 2019
                : 77
                : 2
                : 225-233
                Affiliations
                [1 ]Department of Neuroscience, Mayo Clinic, Jacksonville, Florida
                [2 ]Wien Center for Alzheimer’s Disease and Memory Disorders, Mount Sinai Medical Center, Miami Beach, Florida
                [3 ]Department of Health Sciences Research, Mayo Clinic, Jacksonville, Florida
                [4 ]Department of Neurology, Mayo Clinic, Jacksonville, Florida
                [5 ]Department of Psychiatry and Psychology, Mayo Clinic, Jacksonville, Florida
                Author notes
                Article Information
                Accepted for Publication: August 29, 2019.
                Published Online: October 28, 2019. doi:10.1001/jamaneurol.2019.3606
                Correction: This article was corrected on January 6, 2020, to add additional funding information to Funding/Support.
                Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2019 Hanna Al-Shaikh FS et al. JAMA Neurology.
                Corresponding Author: Melissa E. Murray, PhD, Department of Neuroscience, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224 ( murray.melissa@ 123456mayo.edu ).
                Author Contributions: Dr Murray had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
                Concept and design: Duara, Murray.
                Acquisition, analysis, or interpretation of data: All authors.
                Drafting of the manuscript: Hanna Al-Shaikh, Duara, Lesser, Schaeverbeke, Pedraza, Murray.
                Critical revision of the manuscript for important intellectual content: Duara, Crook, Schaeverbeke, Hinkle, Ross, Ertekin-Taner, Pedraza, Dickson, Graff-Radford, Murray.
                Statistical analysis: Hanna Al-Shaikh, Crook, Lesser, Pedraza, Murray.
                Obtained funding: Ross, Murray.
                Administrative, technical, or material support: Duara, Hinkle, Dickson, Murray.
                Supervision: Duara, Pedraza, Murray.
                Conflict of Interest Disclosures: Dr Duara reported receiving grants from the Florida Department of Health during the conduct of the study; grants from the National Institute on Aging; and personal fees from Med Learning Group, Eli Lilly and Company, and Piramal Imaging outside the submitted work. Dr Ertekin-Taner reported that her husband is the Chief Strategy Officer of Magnolia Health Solutions, LLC, although she has no role in the company and the present study has no connections with the company. Dr Graff-Radford reported receiving grants from Biogen, Novartis, AbbVie, and Eli Lilly and Company outside the submitted work. Dr Murray reported receiving grants from the National Institute on Aging, the Alzheimer’s Association, and the State of Florida during the conduct of the study. No other disclosures were reported.
                Funding/Support: This study was supported by the National Institute on Aging (R01 AG054449 and 1P50 AG047266), the Florida Department of Health, the Ed and Ethel Moore Alzheimer’s Disease Research Program (6AZ01, 8AZ06), a Gerstner Family Career Development Award, and the Alzheimer’s Association (AARG-17-533458). Dr Schaeverbeke received financial support from Fonds voor Wetenschappelijk Onderzoek (V428618N) and Postdoctoral Mandate funding (PDM/17/185) from KU Leuven. This work was supported by funding from the National Institute on Aging Mayo Clinic Alzheimer’s Disease Research Center (P50 AG016574 and P30 AG062677).
                Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
                Additional Contributions: We thank the patients and their families for their generous brain donations to help further our knowledge of Alzheimer disease.
                Article
                noi190088
                10.1001/jamaneurol.2019.3606
                6820048
                31657834
                305b6fab-1a62-4489-a121-b47c39fdf500
                Copyright 2019 Hanna Al-Shaikh FS et al. JAMA Neurology.

                This is an open access article distributed under the terms of the CC-BY License.

                History
                : 20 May 2019
                : 29 August 2019
                Funding
                Funded by: National Institute on Aging
                Funded by: Florida Department of Health
                Funded by: Ed and Ethel Moore Alzheimer’s Disease Research Program
                Funded by: Gerstner Family Career Development Award
                Funded by: Alzheimer’s Association
                Funded by: Fonds voor Wetenschappelijk Onderzoek
                Funded by: KU Leuven
                Categories
                Research
                Research
                Original Investigation
                Featured
                Online First
                Comments

                Comments

                Comment on this article